证券代码：300391 证券简称：*ST 长药 公告编号：2025-080 长江医药控股股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 影响2025年第一季度合并资产负债表、合并现金流量表。 项目及指标有影响。 公司于2025年8月22日召开第六届董事会第二次会议，审议通过了《关于2025 年第一季度财务报告会计差错更正的议案》，同意公司按照《企业会计准则第28 号——会计政策、会计估计变更和差错更正》《公开发行证券的公司信息披露编报 规则第19号——财务信息的更正及相关披露》的相关规定和要求，对相关会计差错 进行更正。公司本次会计差错更正仅涉及2025年第一季度合并利润表，具体情况如 下： 一、会计差错更正情况 《企业会计准则第14号——收入》第三十四条："企业应当根据其在向客户转 让商品前是否拥有对该商品的控制权，来判断其从事交易时的身份是主要责任人还 是代理人。企业在向客户转让商品前能够控制该商品的，该企业为主要责任人，应 当按照已收或应收对价总额确认收入；否则，该企业为代理人，应当按照预期有权 收取的佣金或手续费的金额确认收入 ...

Core Viewpoint - China National Pharmaceutical Group announced the convening of its 30th board meeting on August 8, 2025, to review various proposals, including amendments to existing documents [2] Revenue Composition - For the year 2024, the revenue composition of China National Pharmaceutical Group is as follows: - Pharmaceutical commerce accounts for 77.31% - Pharmaceutical trade accounts for 14.35% - Chemical preparations account for 4.47% - Raw materials account for 2.78% - Traditional Chinese medicine accounts for 1.47% [2]

济民健康（SH 603222，收盘价：6.92元）7月31日晚间发布公告称，截至2025年7月31日，公司通过集 中竞价交易方式累计回购股份约201万股，占公司总股本的比例为0.3819%，购买的最高价为6.13元/ 股，最低价为5.87元/股，已支付的总金额约为1209万元。 2024年1至12月份，济民健康的营业收入构成为：医药制造行业占比55.95%，医疗服务行业占比 41.43%，医药贸易行业占比1.75%，其他业务占比0.87%。 （文章来源：每日经济新闻） ...

Core Viewpoint - Liangshan Jiannada Pharmaceutical Trading Co., Ltd., a subsidiary of Good Doctor Group, has been recognized as an employment internship base in Xichang City, providing more practical opportunities for young talents and injecting new momentum into the company's high-quality development [1][3]. Group 1: Company Overview - Liangshan Jiannada is primarily engaged in the wholesale of pharmaceuticals and medical devices, having maintained steady growth for over a decade [3]. - The company has the largest smart traditional Chinese medicine decoction center and modern cold chain logistics center in the Panxi region, responsible for emergency medical supplies in Liangshan Prefecture and Xichang City [3]. - In 2025, the company plans to launch a fully digital management smart traditional Chinese medicine decoction center with a daily decoction capacity of 2,000 prescriptions, showcasing its advanced technical strength and management level [3]. Group 2: Employment Internship Base - As an employment internship base, Liangshan Jiannada will offer multidimensional practical positions covering pharmaceutical circulation, quality management, and warehouse management, allowing interns to engage with digital processes and cutting-edge industry technologies [3]. - The general manager, Zhang Haiyan, emphasized that the internship base serves as a "incubator" for youth growth and a "report card" for the company's social responsibility [3]. - The recognition as an internship base not only provides skill enhancement opportunities for youth but also lays a solid foundation for the company's talent development, reflecting its commitment to stabilizing employment and promoting development [3].